$2.80
+0.36%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.91
From 52W high−62.67%
Volume33270.00
Market cap$3.76M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$2.91
From 52W high
−62.67%
Volume
33270.00
Market cap
$3.76M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
41.6
MomentumView details →
1D Return
+0.36%
YTD Return
+370.41%
SummaryUpdated Jun 1, 2026
Liminatus Pharma, Inc. (NASDAQ:LIMN) is a clinical-stage biotechnology company founded and based in La Palma, California. The company went public in May 2025, representing a relatively new entrant to the public markets in the immuno-oncology space. As a clinical-stage company, Liminatus is focused on developing novel cancer therapies that harness the body's immune system to fight cancer, though the company is still in early stages of development with no current revenue generation.
Similar companies
Latest newsMore news →
Liminatus Pharma, Inc. agreed to issue 260,001 common shares to a non-U.S. investor in a private placement for gross proceeds of $650,002.50.22h agoLiminatus Pharma regained compliance with Nasdaq's $1 minimum bid price requirement after effecting a 1-for-50 reverse stock split on August 20, 2026.36d ago